We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Zika Vaccine Protects without Inducing Antibody Production

By LabMedica International staff writers
Posted on 02 Jan 2019
A novel vaccine against Zika virus infection, which was successfully tested in mouse models, is based on the delivery of genes for Zika virus structural proteins via attenuated adenovirus vectors. More...


Zika virus (ZIKV), against which there are no approved vaccines, is a major public health concern due to the risk of congenital Zika syndrome in developing fetuses and Guillain-Barre syndrome in adults. Previous studies have shown that due to antibody-dependent enhancement (ADE) of disease, antibodies against Zika virus can worsen Dengue virus infection.

In an attempt to circumvent the ADE problem, investigators at the University of Nebraska, Lincoln (USA) developed two adenovirus (Ad) vectored Zika virus vaccines by inserting a ZIKV prM-E gene expression cassette into human Ad types 4 (Ad4-prM-E) and 5 (Ad5-prM-E). Adenoviruses are safe and highly immunogenic vaccine vectors capable of inducing lasting humoral and cellular immune responses.

Results published in the December 20, 2018, online edition of the journal Scientific Reports revealed that Ad5-prM-E vaccination induced both an anti-ZIKV antibody and T-cell responses whereas Ad4-prM-E vaccination only induced a T-cell response. In a highly lethal challenge in interferon receptor knockout mice, 80% of Ad5 vaccinated animals and 33% of Ad4 vaccinated animals survived a lethal ZIKV challenge, whereas no animals in the sham vaccinated control group survived.

In an infection model utilizing immunocompetent C57BL/6 mice that were immunized and then treated with a blocking anti-IFNAR-1 antibody immediately before ZIKV challenge, 100% of Ad4-prM-E and Ad5-prM-E vaccinated mice survived.

These results showed that Ad4-prM-E vaccination was protective without the development of detectable anti-ZIKV antibodies. Overall, the protection seen in these highly lethal mouse models demonstrated the efficacy of Ad vectored vaccines for use against ZIKV.

"If you have immunity to one of these viruses and get infected by a second one, the illness can be much worse," said senior author Dr. Eric Weaver, assistant professor of biological sciences at the University of Nebraska, Lincoln. "The body makes the wrong immune response."

"To our knowledge, this is the first report of a vaccine that uses the prM-E genes of Zika virus to induce protective immunity without inducing anti-Zika virus antibodies," said Dr. Weaver. "The lack of antibodies may very well circumvent the potential risks of ADE resulting in an effective and safer vaccine than those currently in clinical trials. We hope that we can produce a safer vaccine. If we can figure out the mechanism, we might be able to apply it to other vaccine strategies."

Related Links:
University of Nebraska, Lincoln


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
See-Saw Rocking Shaker
SH-200D-S-L
New
Uric Acid Meter
PA-16
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Gut microbes may help in recognizing and treating pancreatic cancer (Photo courtesy of Adobe Stock)

Gut Microbes Could Enable Early Detection and Treatment of Pancreatic Cancer

Pancreatic cancer remains one of the most serious and challenging diseases in oncology due to its difficulty in detection and limited treatment options. Now, a new international collaborative study suggests... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.